-
Primary care and community-based screening for Chagas disease in London, United Kingdom, August 2023 to January 2025
-
View Affiliations Hide AffiliationsCorrespondence:Natalie Elkheirnatalie.elkheir lshtm.ac.uk
-
View Collaborators
Primary Care Delivery Team: Silvia Gonzalez, Cristian Pico, Lukasz Radwanski, Antoinette McNulty, Marcelle Costa Marinho, Ashnee Dhondee, Zara Prem, Aldrich Menezes, Jasdeep Bhamrah, Martynas Stonkus, Wan Sze Shum, Monica Morim, Zuhaib Keekeebai, Alaliba Dokubo-Oguwuike, Desiree Fyle, Miguel Gonzalez Oquendo, Sobhash Jhuree, Yusuf Kabir, Maykon Melo, Moyosore Olukoga;UK Chagas Hub Volunteers: Nuria Sanchez Clemente, Ana García Mingo, Liliana Sanchez Zelaya, Laura Valderrama Penagos, Laura Lopez, Rodrigo Ville, Estefania Sienra-Iracheta, Temitope Fisayo, Pat Lok, Fionnuala Ryan, Ana Bayona, Jose Garcia Romero, Clare E. Warrell, Nicolas Massie, Cristina Fernandez-Turienzo, Valentina De Sario, Jenna Abaakouk, Karina Guzman Miranda, Cristina Suarez, Maria-Cristina Loader, Catherine Dominic, Marcela Bojorquez Segura, Heloise Gerber, Anna Bote-Casamitjana, Patricia Miralhes, Alyssa Chase-Vilchez, Amaya Bustinduy, Declan Crilly, Jaimie Wilson-Goldsmith, Barbara de BarrosView Citation Hide Citation
Citation style for this article: . Primary care and community-based screening for Chagas disease in London, United Kingdom, August 2023 to January 2025. Euro Surveill. 2026;31(6):pii=2500365. https://doi.org/10.2807/1560-7917.ES.2026.31.6.2500365 Received: 24 May 2025; Accepted: 20 Oct 2025
Abstract
Chagas disease (CD), a tropical parasitic disease caused by Trypanosoma cruzi, is increasingly recognised as a public health concern among Latin American migrants living in non-endemic settings. In London, United Kingdom (UK), home to over 160,000 people from endemic countries, no formal population-level CD screening programmes exist.
To investigate the seroepidemiology of CD infection in Latin American adults living in London, UK.
A cross-sectional, observational study utilising questionnaires and serological (T. cruzi) screening was performed between August 2023 and January 2025. Adults born in South America, Central America or Mexico (or whose mothers were born there) were eligible to participate. Screening was offered in primary care sites and by point-of-care serological testing at community events. Outcomes were seroprevalence, screening yield, positive predictive value of screening tests and linkage to care.
In primary care, of 2,739 eligible individuals offered screening, 276 (10.1%) accepted. At community events, 247 were screened. Of the 523 screened, 20 (3.8%) participants had positive screening tests, and CD was confirmed in 14 (2.7%), all born in Bolivia. Seroprevalence was lower in those screened in primary care (1.1%) than at community events (4.5%). The number needed to screen to detect one confirmed case (linked into care) was 37 overall, 92 in primary care and 22 at community events.
Screening for CD through primary care in the UK is highly challenging, with both low uptake and low yield amongst those tested. Targeted community-based outreach approaches result in higher screening yield and linkage to care.
Full text loading...


